(R)-2-(3-methylpyrrolidin-1-yl)ethanamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (R)-2-(3-methylpyrrolidin-1-yl)ethanamine
• 英文别名: 2-[(3R)-3-methylpyrrolidin-1-yl]ethan-1-amine；2-[(3R)-3-methylpyrrolidin-1-yl]ethanamine
• 化学式: C₇H₁₆N₂
• 分子量: 128.217
• InChiKey: DXDQFNSYQQZGCG-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-methyl-5-((1-methyl-6-(pyrimidin-5-ylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)amino)nicotinic acid 、 (R)-2-(3-methylpyrrolidin-1-yl)ethanamine 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以23.9 mg的产率得到(R)-6-methyl-5-((1-methyl-6-(pyrimidin-5-ylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)amino)-N-(2-(3-methylpyrrolidin-1-yl)ethyl)nicotinamide
  参考文献：
  名称：

  [EN] PYRAZOLOPYRIMIDINES AND THEIR USES AS PDGFR INHIBITORS
  [FR] PYRAZOLOPYRIMIDINES ET LEURS UTILISATIONS EN TANT QU'INHIBITEURS DE PDGFR

  摘要：

  The disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of formula (I), as well as methods of their use and preparation, are also described.

  公开号：

  WO2023007009A1
• 作为产物：
  描述：

  (R)-2-(3-methylpyrrolidin-1-yl)acetonitrile 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 (R)-2-(3-methylpyrrolidin-1-yl)ethanamine
  参考文献：
  名称：

  [EN] PYRAZOLOPYRIMIDINES AND THEIR USES AS PDGFR INHIBITORS
  [FR] PYRAZOLOPYRIMIDINES ET LEURS UTILISATIONS EN TANT QU'INHIBITEURS DE PDGFR

  摘要：

  The disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of formula (I), as well as methods of their use and preparation, are also described.

  公开号：

  WO2023007009A1

文献信息

• [EN] PYRAZOLOPYRIMIDINES AND THEIR USES AS PDGFR INHIBITORS<br/>[FR] PYRAZOLOPYRIMIDINES ET LEURS UTILISATIONS EN TANT QU'INHIBITEURS DE PDGFR
  申请人：[en]ACTELION PHARMACEUTICALS LTD

  公开号：WO2023007009A1

  公开（公告）日：2023-02-02

  The disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of formula (I), as well as methods of their use and preparation, are also described.